+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Electrophysiological effects of sotalol in supraventricular tachycardias

Zeitschrift fuer Kardiologie 74(9): 506-511

Electrophysiological effects of sotalol in supraventricular tachycardias

The electrophysiological effects of sotalol, a beta-blocking drug with class III antiarrhythmic properties were assessed in 20 patients (mean age 33 .+-. 14.3 years) with supraventricular tachycardias. Sixteen patients had Wolff-Parkinson-White syndrome (overt n = 9, concealed n = 7), three patients AV-nodal reentrant tachycardias and another patient atrial tachycardias. Sotalol was administered intravenously (n = 16) in a dose of 1.5 mg/kg over 15 min. The effects of 320 to 480 mg/day oral sotalol were assessed in 7 patients. By intravenous and oral application of sotalol a significant increase in the AH interval, the refractory periods of the atrium and ventricle as well as a decrease of the antegrade and retrograde conduction capacity of the AV node or the accessory pathway were observed. The mean R-R interval during induced atrial fibrillation increased significantly in patients with Wolff-Parkinson-White syndrome from 224 .+-. 52 ms to 277 .+-. 59 ms (p < 0.05). In 10 patients, sotalol was administered during supraventricular reentrant tachycardia. The cycle length of supraventricular tachycardia increased from 276 .+-. 90 ms to 358 .+-. 25 ms (p < 0.01). The tachycardia terminated in 7 patients: in 5 patients block was observed in the AV node, while in another 2 patients tachycardia terminated retrogradely. After intravenous application supraventricular arrhythmias were no longer inducible in 5 of 12 patients. In a further 4 patients only non-sustained supraventricular tachycardias (4-20 QRS complexes) were inducible. In 2 patients the supraventricular tachycardia terminated distal to the His bundle. Thus, sotalol was effective in the treatment of supraventricular tachycardias. The drug prolonged myocardial refractoriness acutely and chronically. Its antiarrhythmic efficacy can be ascribed to its prolongation of refractoriness (class III activity).

(PDF 0-2 workdays service: $29.90)

Accession: 005349597

Related references

Sotalol for paroxysmal supraventricular tachycardias. American Journal of Cardiology 65(2): 67a-73a; Discussion 82a-83a, 1990

Electrophysiological effects of nicainoprol in patients with paroxysmal supraventricular tachycardias. International Journal of Cardiology 29(2): 221-228, 1990

Anti-arrhythmia and electrophysiological effects of encainide in supraventricular tachycardias. Archives des Maladies du Coeur et des Vaisseaux 78 Spec No: 113-119, 1985

Electrophysiologic effect of sotalol in supraventricular tachycardias. Zeitschrift für Kardiologie 74(9): 506-511, 1985

Electrophysiological effects and clinical efficacy of flecainide in patients with supraventricular tachycardias. American Heart Association Monograph: Ii-103, 1986

Sotalol versus verapamil in the treatment of paroxysmal supraventricular tachycardias. Circulation 80(4 SUPPL 2): II633, 1989

Efficacy of intravenous sotalol for suppressing inducibility of supraventricular tachycardias at rest and during exercise. European Heart Journal 12(ABSTR SUPPL): 223, 1991

Electrophysiological effects of intravenous and oral propafenone in patients with supraventricular paroxysmal tachycardias: correlation with drug blood levels. Revista Espanola de Cardiologia 38(3): 198-202, 1985

Efficacy of intravenous sotalol for suppressing inducibility of supraventricular tachycardias at rest and during isometric exercise. American Journal of Cardiology 69(5): 498-502, 1992

Mechanisms of termination of supraventricular tachycardias by intravenous class III antiarrhythmic agents. A comparison of amiodarone and sotalol. European Heart Journal 10(12): 1084-1089, 1989